Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Κυριακή 21 Ιουνίου 2020


Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer
Background To the authors' knowledge, there are no approved therapies for recurrent, metastatic (R/M) salivary gland carcinoma (SGC), but molecularly targeted therapies warrant ongoing investigation. In the current study, the authors have reported on the efficacy of tipifarnib in patients with aggressive HRAS ‐mutant, R/M SGC. Methods The current prospective, nonrandomized, multicenter, international cohort study involved 8 centers and was conducted from May 2015 to June 2019. The median follow‐up...
Cancer
Thu Jun 18, 2020 16:37
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey
Background Li‐Fraumeni syndrome (LFS) is a high‐risk cancer predisposition syndrome caused by pathogenic germline variants of TP53 . Cancer surveillance has noted a significant survival advantage in individuals with LFS; however, little is known about the feasibility, acceptance, and psychosocial effects of such a program. Methods Pathogenic TP53 germline variant carriers completed a 7‐part questionnaire evaluating sociodemographics, cancer history, surveillance participation, reasons for...
Cancer
Thu Jun 18, 2020 16:37
HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors
Abstract Adult T cell leukemia‐lymphoma (ATL) is a peripheral T cell malignancy caused by human T cell leukemia virus–type 1 (HTLV‐1).1 Frequent structural variations that disrupt the 3' untranslated region of the programmed cell death–ligand 1 (PD‐L1) gene have been found to result in overexpression of PD‐L1 in ATL patients.2 The programmed cell death–1 (PD‐1)–PD‐L1 axis has thus attracted attention as a potential therapeutic target for ATL. However, in a phase 2 trial of the PD‐1 inhibitor nivolumab...
Cancer Science
Thu Jun 18, 2020 18:04
The miR‐1908/SRM regulatory axis contributes to extracellular vesicle secretion in prostate cancer
Abstract Targeting the extracellular vesicle (EV) secretion can have potential clinical implications for cancer therapy; however, the precise regulatory mechanisms of EV secretion are not fully understood. Recently, we have shown a novel pathway of EV biogenesis in PCa cell lines, PC3 and PC3M. However, since the characteristics of EVs were divergent even among PCa cell lines, we hypothesized that other pathways or common regulatory pathways of EV biogenesis still exist. Here, we performed quantitative...
Cancer Science
Thu Jun 18, 2020 18:04
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
Purpose: This phase 2 study (NCT03469557) assessed safety/tolerability and antitumor activity of first line tislelizumab, a monoclonal antibody against PD-1, plus chemotherapy in patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) or gastric cancer/gastroesophageal junction (G/GEJ) adenocarcinoma. Experimental Design: Patients with ESCC received tislelizumab (200mg IV every 3 weeks [Q3W]) plus cisplatin (80mg/m² IV Q3W for ≤6 cycles) and fluorouracil (800mg/m²/d,...
Clinical Cancer Research Online First Articles
Fri Jun 19, 2020 16:31
Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer
Purpose: To evaluate the relationship between exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, and selected clinical efficacy and safety parameters in men with high risk non-metastatic castration-resistant prostate cancer. Patients and Methods: An exploratory exposure-response analysis was undertaken using data from the 1207 patients (806 apalutamide and 401 placebo) enrolled in the SPARTAN study, including those who had undergone dose reductions and dose interruptions....
Clinical Cancer Research Online First Articles
Fri Jun 19, 2020 16:31
Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer
Purpose: Invasive lobular carcinoma (ILC) accounts for approximately 5-15% of all invasive breast cancer cases. Most of the correlations between multigene assays and patient outcome were derived from studies based on patients with invasive ductal carcinoma (IDC) or without distinction between the subtypes. Here, we investigate the prognostic value of EndoPredict in a large cohort of ILCs pooled from three phase III randomized trials (ABCSG-6, ABCSG-8, TransATAC). Experimental Design: The primary...
Clinical Cancer Research Online First Articles
Fri Jun 19, 2020 16:31
Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma
Publication date: August 2020Source: European Journal of Cancer, Volume 135Author(s): Henry G. Smith, Jessica Glen, Nancy Turnbull, Howard Peach, Ruth Board, Miranda Payne, Martin Gore, Karen Nugent, Myles J.F. Smith
European Journal of Cancer
Fri Jun 19, 2020 16:41
Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study
Publication date: August 2020Source: European Journal of Cancer, Volume 135Author(s): Yihui Du, Grigory Sidorenkov, Marjolein A. Heuvelmans, Harry J.M. Groen, Karin M. Vermeulen, Marcel J.W. Greuter, Geertruida H. de Bock
European Journal of Cancer
Fri Jun 19, 2020 16:41
A common source for a trichinellosis outbreak reported in France and Serbia in 2017
Trichinellosis is a rare parasitic zoonosis in the European Union. Meat from backyard pigs was the common source for a trichinellosis outbreak caused by Trichinella spiralis, which occurred in France and Serbia in the beginning of 2017. An epidemiological study was conducted in France and Serbia to determine the extent of the outbreak, to identify its source and to implement control measures. Three cases were exposed in Serbia and brought back to France pork delicatessen which they shared with relatives...
Eurosurveillance latest updates
Thu Jun 18, 2020 03:00
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020
We evaluated SARS-CoV-2 RNA and neutralising antibodies in blood donors (BD) residing in the Lodi Red Zone, Italy. Of 390 BDs recruited after 20 February 2020 − when the first COVID-19 case in Lombardy was identified, 91 (23%) aged 19–70 years were antibody positive. Viral RNA was detected in an additional 17 (4.3%) BDs, yielding ca 28% (108/390) with evidence of virus exposure. Five stored samples collected as early as 12 February were seropositive.
Eurosurveillance latest updates
Thu Jun 18, 2020 03:00
Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020
Containment strategies and clinical management of coronavirus disease (COVID-19) patients during the current pandemic depend on reliable diagnostic PCR assays for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we compare 11 different RT-PCR test systems used in seven diagnostic laboratories in Germany in March 2020. While most assays performed well, we identified detection problems in a commonly used assay that may have resulted in false-negative test results during the first...
Eurosurveillance latest updates
Thu Jun 18, 2020 03:00
Authors’ correction for Euro Surveill. 2020;25(23)
Eurosurveillance latest updates
Thu Jun 18, 2020 03:00
A novel translocation t(10;17)(p13;q11.2) harboring two cryptic deletions identified by array‐CGH and characterized by SUZ12 overexpression in a patient with chronic thrombocytosis
Abstract No specific translocation is associated with myeloproliferative neoplasms (MPNs). However, an interstitial deletion involving sub‐band 17q11.2 which includes the NF1 gene, although rare, is a recurrent aberration in several myeloid disorders including MPNs. For the first time, we report an acquired novel translocation involving 10p13 and 17q11.2 in a 62‐year‐old Caucasian female which was referred for investigation of chronic and persistent unexplained thrombocytosis. The patient had no...
Genes, Chromosomes and Cancer
Fri Jun 19, 2020 14:49
Real‐world outcomes of advanced melanoma patients not represented in phase III trials
Abstract The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision‐making. Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune‐ or targeted therapy, who met ≥1 trial exclusion criteria. These criteria were derived from the KEYNOTE‐006 and CHECKMATE‐067/−066 phase III trials. Prognostic importance of factors associated with overall...
International Journal of Cancer
Fri Jun 19, 2020 13:20
KSHV dysregulates bulk macroautophagy, mitophagy and UPR to promote endothelial to mesenchymal transition and CCL2 release, key events in viral‐driven sarcomagenesis
Abstract Kaposi's Sarcoma‐associated Herpesvirus (KSHV) is the causative agent of KS, an aggressive neoplasm that mainly occurs in immune‐compromised patients. Spindle cells represent the main feature of this aggressive malignancy and arise from KSHV‐infected endothelial cells undergoing endothelial to mesenchymal transition (EndMT), which changes their cytoskeletal composition and organization. As in epithelial to mesenchymal transition (EMT), EndMT is driven by transcription factors such as SNAI1...
International Journal of Cancer
Fri Jun 19, 2020 13:19
A Phase II Study of Anlotinib in Forty‐five Patients with Relapsed Small Cell Lung Cancer
Abstract The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued for 7 days, and repeated every 21 days) until disease progression or intolerance of treatment. The primary end point was progression‐free survival (PFS). Secondary end points were overall survival...
International Journal of Cancer
Thu Jun 18, 2020 22:00
Worrying About Death: An Initial Analysis of Young Adult Cancer Patients' Needs
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Journal of Adolescent and Young Adult Oncology
Thu Jun 18, 2020 10:00
Knowledge Levels of Kindergarten Teachers About Skin Cancer, Sun Protection Behaviors, and Affecting Factors
Abstract The aim of this study was to determine the knowledge level of kindergarten teachers regarding skin cancer, the sun protection behaviors they exhibit for themselves/their students, and the affecting factors. This descriptive study was carried out in the Mediterranean region in a province located by the sea. The universe of the study consisted of 181 teachers working in kindergartens, and data were collected from the 81% who agreed to participate in the study. The mean...
Journal of Cancer Education
Sun Jun 21, 2020 03:00
The Role of Vaccination Interventions to Promote HPV Vaccine Uptake Rates in a College-Aged Population: a Systematic Review
Abstract This systematic review provided synthesized evidence regarding the effectiveness of the interventions promoting the human papillomavirus (HPV) vaccination in college-aged population. The HPV infection is the most prevailing sexually transmitted disease. Despite the availability and effectiveness of the 9-Valent HPV vaccine, the vaccine coverage among young adults remained low. In witness to the increasing burden of HPV-related infections and cancers, research focused...
Journal of Cancer Education
Sun Jun 21, 2020 03:00
Effectiveness of Decision Aid in Men with Localized Prostate Cancer: a Multicenter Randomized Controlled Trial at Tertiary Referral Hospitals in an Asia Pacific Country
Abstract There are several treatment options for localized prostate cancer with very similar outcome but vary in terms of technique and side effect profiles and risks. Considering the potential difficulty in choosing the best treatment, a patient decision aid (PDA) is used to help patients in their decision-making process. However, the use and applicability of PDA in a country in Asia Pacific region like Malaysia is still unknown. This study aims to evaluate the effectiveness...
Journal of Cancer Education
Sat Jun 20, 2020 03:00
Implementing Community-Based Prostate Cancer Education in Rural South Carolina: a Collaborative Approach Through a Statewide Cancer Alliance
Abstract The purpose of this study was to evaluate the impact of implementing community-based prostate health education programs in rural communities. Prostate cancer (PrCA) remains one of the most common cancers among men, and a growing body of literature demonstrates that large interracial differences in PrCA incidence and mortality rates consistently disfavor African Americans in comparison to European Americans. It also is evident, despite the overall decrease in cancer death...
Journal of Cancer Education
Sat Jun 20, 2020 03:00
The Connection Between Social Determinants of Health and Human Papillomavirus Testing Knowledge Among Women in the USA
Abstract Human papillomavirus (HPV) causes 99% of cervical cancers. In the USA, HPV testing has recently been recommended as a stand-alone option for cervical cancer screening in women over 30 years of age. Yet, studies have shown low awareness of HPV testing. This study examines awareness and knowledge that US women possess regarding HPV testing using the social determinants of health (SDOH) framework. Women aged 30 to 65 years, without hysterectomy, completed an online survey...
Journal of Cancer Education
Sat Jun 20, 2020 03:00
Expanding Our Reach: the Value of Massage Therapists in Melanoma Identification
Abstract Massage therapists are uniquely positioned to identify skin cancer. Seminal work in 2013 revealed that 40% of massage therapists do not receive any training in skin cancer identification (Campbell et al. J Cancer Educ 28:158–164, 2013). Limited work has been published assessing optimal training methodologies to close this educational gap. We present the results of a study in which students were given access to a 30-min self-driven web-based learning module designed to...
Journal of Cancer Education
Sat Jun 20, 2020 03:00
Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are candidates for therapeutic interventio...
Journal of Experimental & Clinical Cancer Research - Latest Articles
Sat Jun 20, 2020 03:00
HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395
Aberrant alternative splicing events play critical roles in carcinogenesis and progression of many cancers, while sparse studies regarding to alternative splicing are available for clear cell renal cell carcin...
Journal of Experimental & Clinical Cancer Research - Latest Articles
Fri Jun 19, 2020 03:00
Loss of prdm1a accelerates melanoma onset and progression
Abstract Melanoma is an aggressive, deadly skin cancer derived from melanocytes, a neural crest cell derivative. Melanoma cells mirror the developmental program of neural crest cells in that they exhibit the same gene expression patterns and utilize similar cellular mechanisms, including increased cell proliferation, epithelial‐mesenchymal transition, and migration. Here we studied the role of neural crest regulator PRDM1 in melanoma onset and progression. In development, Prdm1a functions to promote...
Molecular Carcinogenesis
Sat Jun 20, 2020 14:09
Fibroblast growth factor‐2, derived from cancer‐associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling
Abstract Cancer‐associated fibroblasts (CAFs) constitute a major compartment of the tumor microenvironment. In the present study, we investigated the role for CAFs in breast cancer progression and underlying molecular mechanisms. Human breast cancer MDA‐MB‐231 cells treated with the CAF‐conditioned media manifested a more proliferative phenotype, as evidenced by enhanced messenger RNA (mRNA) expression of Cyclin D1, c‐Myc, and proliferating cell nuclear antigen. Analysis of data from The Cancer...
Molecular Carcinogenesis
Thu Jun 18, 2020 20:21
Cancer, Coronavirus and the Magic of Little Richard
Publication date: Available online 19 June 2020Source: Practical Radiation OncologyAuthor(s): Mark J. Stavas
Practical Radiation Oncology
Fri Jun 19, 2020 14:02
Adoption of expansion margins to reduce the dose received by the coronary arteries and the risk of cardiovascular events in lymphoma patients
Publication date: Available online 19 June 2020Source: Practical Radiation OncologyAuthor(s): Viola De Luca, Elena Gallio, Sara Bartoncini, Francesca Romana Giglioli, Anna Sardo, Chiara Cavallin, Giuseppe Carlo Iorio, Erika Orlandi, Ramona Parise, Carmela Palladino, Alberto Buonavita, Christian Fiandra, Mario Levis, Umberto Ricardi
Practical Radiation Oncology
Fri Jun 19, 2020 14:02
Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial
The objectives of this study were to determine the objective effective response rate, survival, and safety of radiotherapy combined with gefitinib in patients with locally advanced non-small cell lung cancer (...
Radiation Oncology - Latest Articles
Sat Jun 20, 2020 03:00
Estimation of the performance of a risk prediction model for gastric cancer occurrence in Japan: Evidence from a small external population
Publication date: August 2020Source: Cancer Epidemiology, Volume 67Author(s): Hadrien Charvat, Taichi Shimazu, Manami Inoue, Motoki Iwasaki, Norie Sawada, Taiki Yamaji, Shoichiro Tsugane, for the JPHC Study Group
ScienceDirect Publication: Cancer Epidemiology (open access)
Sat Jun 20, 2020 15:03
outside front cover
Publication date: April–June 2020Source: Seminars in Oncology, Volume 47, Issues 2–3Author(s):
Seminars in Oncology
Sat Jun 20, 2020 15:38
TOC
Publication date: April–June 2020Source: Seminars in Oncology, Volume 47, Issues 2–3Author(s):
Seminars in Oncology
Sat Jun 20, 2020 15:38
Editorial Board
Publication date: April–June 2020Source: Seminars in Oncology, Volume 47, Issues 2–3Author(s):
Seminars in Oncology
Sat Jun 20, 2020 15:38
Masthead
Publication date: April–June 2020Source: Seminars in Oncology, Volume 47, Issues 2–3Author(s):
Seminars in Oncology
Sat Jun 20, 2020 15:38
Distribution of cancer genes in human chromosomes
Publication date: Available online 19 June 2020Source: Seminars in OncologyAuthor(s): Bahar Laderian, Mengxi Zhou, Tito Fojo
Seminars in Oncology
Fri Jun 19, 2020 15:23
Superoxiddismutasemimetikum (GC4419) vs. Placebo zur Reduktion von schweren oralen Mukositiden infolge simultaner Radiochemotherapie mit Cisplatin bei Kopf-Hals-Tumoren: randomisierte, doppelblinde Phase-IIb-Studie
Strahlentherapie und Onkologie
Fri Jun 19, 2020 03:00
Einfluss der Behandlungscompliance auf den Erfolg der Radiochemotherapie des Analkarzinoms
Strahlentherapie und Onkologie
Fri Jun 19, 2020 03:00
A randomized in vitro evaluation of transient and permanent cardiac implantable electronic device malfunctions following direct exposure up to 10 Gy
Abstract Background and purpose High-dose 6‑MV radiotherapy may cause cardiac implantable electronic devices (CIEDs) to malfunction. To assess CIED malfunctions resulting from direct exposure up to 10 Gy, 100 pacemakers (PMs) and 40 implantable cardioverter-defibrillators (ICDs) were evaluated. Materials and methods CIEDs underwent baseline interrogation....
Strahlentherapie und Onkologie
Fri Jun 19, 2020 03:00
Pembrolizumab in der neoadjuvanten Behandlung des frühen triple-negativen Mammakarzinoms
Strahlentherapie und Onkologie
Fri Jun 19, 2020 03:00
Die Herzmortalität nach Strahlentherapie, Chemotherapie und endokriner Therapie des Mammakarzinoms
Strahlentherapie und Onkologie
Fri Jun 19, 2020 03:00
Adjuvante Chemotherapie in der Behandlung der Urothelkarzinome des oberen Harntraktes
Strahlentherapie und Onkologie
Fri Jun 19, 2020 03:00

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου